What are the adjunctive treatments used for fibrinolysis or PCI in ACS?

In the context of acute coronary syndrome (ACS), adjunctive treatments used alongside fibrinolysis or percutaneous coronary intervention (PCI) play a crucial role in improving outcomes. Antiplatelets and anticoagulants are considered the standard adjunctive therapies in this scenario.

Antiplatelet agents, such as aspirin and P2Y12 inhibitors (e.g., clopidogrel, ticagrelor), help prevent further platelet activation and aggregation, reducing the risk of thrombus formation following the initial reperfusion therapy. This is essential because even after restoring blood flow to the myocardium, there's still a risk of further ischemic events due to residual thrombus or new thrombus formation.

Anticoagulants, like heparin or low molecular weight heparin, are used to inhibit further coagulation and prevent the enlargement of existing clots. They function by different mechanisms compared to antiplatelets and work synergistically to optimize clot management during and after the acute event.

The combination of anticoagulants and antiplatelets enhances the efficacy of the primary treatment—fibrinolytics or PCI—by addressing different pathways in the coagulation process, ultimately leading to better preservation of myocardial tissue and improved patient outcomes.

Other options, such